Which statement about nonverbal communication is accurate?

Choice A reason: Legislation changing civil commitment procedures occurred later, notably in the 1960s–1970s, with deinstitutionalization movements. In the 1950s, institutional care was still prevalent, and legislative reforms were not the primary change in mental health treatment, making this option incorrect for that decade.

Choice B reason: Community support services expanded significantly during the 1960s with deinstitutionalization, not the 1950s. While some early community efforts existed, they were not the hallmark change of the 1950s, when institutional care dominated, and psychotropic drugs revolutionized treatment approaches for mental illness.

Choice C reason: The Patient’s Bill of Rights was formalized in the 1970s, not the 1950s. While patient advocacy began to emerge later, the 1950s focused primarily on medical advancements like psychotropic drugs, not legal frameworks for patient rights, making this option incorrect.

Choice D reason: In the 1950s, psychotropic drugs like chlorpromazine were introduced, revolutionizing mental health treatment. These medications effectively managed psychosis, reducing symptoms and enabling outpatient care, decreasing reliance on long-term institutionalization. This marked a significant shift in psychiatric care, making it the key change of the decade.

Choice A reason: Antihypertensives are routinely used in ESRD to manage hypertension caused by fluid overload and renin-angiotensin system dysregulation. Controlling blood pressure prevents cardiovascular complications like heart failure or stroke, which are common in ESRD due to chronic volume and pressure overload, making this medication appropriate.

Choice B reason: ADH is not used in ESRD, as it promotes water reabsorption, worsening fluid overload in anuric patients. ESRD patients rely on dialysis for fluid balance, and ADH could exacerbate hypertension or pulmonary edema. Its use is more relevant in conditions like diabetes insipidus, not renal failure.

Choice C reason: Erythrocyte-stimulating agents, like erythropoietin, are standard in ESRD to treat anemia caused by reduced erythropoietin production by failing kidneys. These agents stimulate red blood cell production, improving oxygen delivery and reducing fatigue, making them essential for managing ESRD-related anemia and improving quality of life.

Choice D reason: Phosphate binders are used in ESRD to manage hyperphosphatemia by binding dietary phosphate in the gut, preventing its absorption. This reduces the risk of vascular calcification and secondary hyperparathyroidism, common complications in ESRD due to impaired phosphate excretion, making these medications a standard part of therapy.